U.S., Aug. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07124793) titled 'A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors' on Aug. 07.
Brief Summary: CIBI363A203, a Phase 2 study to evaluate the safety, tolerability and preliminary efficacy of IBI363 combined with IBI305 (a bevacizumab biosimilar) in participants with advanced malignancies conducted in China. Primary endpoint is objective response rate (ORR) per RECIST v1.1. Secondary endpoints include DoR, DCR, TTR, PFS, per RECIST v1.1, and OS; the incidence and severity of AEs, irAEs, SAEs, AESIs and their relationship to the investigational drug, and changes in vital signs, physical examination, and laboratory values b...